adagrasib (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Non-small Cell Lung Cancer

Pending FDA approvals for patients with non-small cell lung cancer (NSCLC) that harbors the KRASG12C mutation who have received ≥1 prior systemic therapy

Next:

Pharmacology

Mechanism of Action

Inhibits KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C-mutated cancers, since the KRASG12C protein regenerates every 24-48 hr

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.